Clinical and pathological features of an Alzheimer's disease patient with the MAPT Delta K280 mutation
about
Frontotemporal lobar degeneration: old knowledge and new insight into the pathogenetic mechanisms of tau mutationsDisrupting self-assembly and toxicity of amyloidogenic protein oligomers by "molecular tweezers" - from the test tube to animal modelsInvited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimagingRare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease familiesPreventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau.Hirano bodies differentially modulate cell death induced by tau and the amyloid precursor protein intracellular domain.Pro-aggregant Tau impairs mossy fiber plasticity due to structural changes and Ca(++) dysregulationNew approaches to genetic counseling and testing for Alzheimer's disease and frontotemporal degenerationPathological Tau Promotes Neuronal Damage by Impairing Ribosomal Function and Decreasing Protein SynthesisThe aqueous extract of Glycyrrhiza inflata can upregulate unfolded protein response-mediated chaperones to reduce tau misfolding in cell models of Alzheimer's disease.The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features.C9orf72 hexanucleotide repeat expansions in clinical Alzheimer diseaseAdenosine A1 receptor antagonist rolofylline alleviates axonopathy caused by human Tau ΔK280Tau alternative splicing in familial and sporadic tauopathies.Alzheimer's disease genetics: from the bench to the clinic.The Role of the Carboxyl-Terminal Sequence of Tau and MAP2 in the Pathogenesis of DementiaEarly-Onset Alzheimer Disease and Candidate Risk Genes Involved in Endolysosomal Transport.The Distance between N and C Termini of Tau and of FTDP-17 Mutants Is Modulated by Microtubule Interactions in Living Cells.Correction of tau mis-splicing caused by FTDP-17 MAPT mutations by spliceosome-mediated RNA trans-splicing.Analysis of in vivo turnover of tau in a mouse model of tauopathy.The Potential of Indole/Indolylquinoline Compounds in Tau Misfolding Reduction by Enhancement of HSPB1.Anti-aggregant tau mutant promotes neurogenesis.Interplay of pathogenic forms of human tau with different autophagic pathways.Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia
P2860
Q26777247-A12271EA-FC57-4807-8A29-1A660D1127B2Q26995918-31E29519-CB5F-4D73-BE2C-AFC42084BA93Q27020981-F1E0D8B8-9A11-4D0D-8E51-05673A21A69FQ28732285-60061837-D5FE-49CC-A7BD-BBD8D36EF56DQ30649677-699A07F2-BF32-4B8B-9F35-8980949182F8Q31165645-30185F62-B225-4F1F-893E-71871CD64CEEQ35258352-B9595B09-D763-4090-BEC9-973172BFCA67Q36218610-642D5B8F-08ED-4282-9C14-10F103208D54Q36480214-63A78899-8931-45A5-9E06-CFA16BA192C6Q36653085-E206C0F5-C2D2-412E-B05C-26A2CF553B77Q36852789-ABE014AB-73B1-451A-B7AE-367A78612638Q36926919-8282FA37-B65F-410B-B0BF-D114917751FFQ37346791-CE94211D-B406-431C-AB34-A3B42BE17B7DQ38027938-4CE06B75-66BB-407F-B540-00096353CDB0Q38225911-C99DFB55-40B9-4197-858F-B3D9AF8D445CQ39084544-17644D51-3CA2-48AF-BDD2-6EE4CD20C75CQ40110802-C552D269-8CAA-400F-B97F-3F50496C66A1Q40990185-21334EBD-8BA3-4340-A82D-DBFE446FF43CQ42020807-FB43EBF6-EC8F-44E4-A55C-CB2E998BC13CQ42117797-D16AF89C-F3CC-4414-88C3-41C4FC51AA41Q46515336-A91575B0-D054-4E07-9A93-4D3C269B6A31Q47116879-0306771B-DD7E-43AB-A647-C06C165CC137Q47662313-357D511D-E93D-437B-95B5-337E2AA40B20Q56972630-109F74B6-3454-454A-899E-31BCA1A18CBE
P2860
Clinical and pathological features of an Alzheimer's disease patient with the MAPT Delta K280 mutation
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 August 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical and pathological feat ...... h the MAPT Delta K280 mutation
@en
Clinical and pathological feat ...... the MAPT Delta K280 mutation.
@nl
type
label
Clinical and pathological feat ...... h the MAPT Delta K280 mutation
@en
Clinical and pathological feat ...... the MAPT Delta K280 mutation.
@nl
prefLabel
Clinical and pathological feat ...... h the MAPT Delta K280 mutation
@en
Clinical and pathological feat ...... the MAPT Delta K280 mutation.
@nl
P2093
P2860
P50
P1476
Clinical and pathological feat ...... h the MAPT Delta K280 mutation
@en
P2093
Christine Hulette
Connie Luk
Elke Malzer
Jana Vandrovcova
Rohan de Silva
Tamas Revesz
Tammaryn Lashley
P2860
P304
P356
10.1016/J.NEUROBIOLAGING.2007.07.013
P577
2007-08-27T00:00:00Z